AstraZeneca (AZN) stock rises after successful Enhertu Phase 3 trial demonstrates improved outcomes in HER2-mutant lung cancer first-line treatment. The post AstraZeneca (AZN) Stock Climbs on Promising Enhertu Cancer Trial Data appeared first on Blockonomi.